Iovance Biotherapeutics Inc
NASDAQ:IOVA

Watchlist Manager
Iovance Biotherapeutics Inc Logo
Iovance Biotherapeutics Inc
NASDAQ:IOVA
Watchlist
Price: 7.38 USD 2.22%
Market Cap: 2.2B USD
Have any thoughts about
Iovance Biotherapeutics Inc?
Write Note

Iovance Biotherapeutics Inc
Research & Development

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Iovance Biotherapeutics Inc
Research & Development Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Research & Development CAGR 3Y CAGR 5Y CAGR 10Y
Iovance Biotherapeutics Inc
NASDAQ:IOVA
Research & Development
-$297.6m
CAGR 3-Years
-8%
CAGR 5-Years
-16%
CAGR 10-Years
-69%
Abbvie Inc
NYSE:ABBV
Research & Development
-$7.9B
CAGR 3-Years
-4%
CAGR 5-Years
-9%
CAGR 10-Years
-10%
Gilead Sciences Inc
NASDAQ:GILD
Research & Development
-$5.5B
CAGR 3-Years
-4%
CAGR 5-Years
10%
CAGR 10-Years
-9%
Amgen Inc
NASDAQ:AMGN
Research & Development
-$5.8B
CAGR 3-Years
-7%
CAGR 5-Years
-8%
CAGR 10-Years
-3%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Research & Development
-$3.5B
CAGR 3-Years
-7%
CAGR 5-Years
-15%
CAGR 10-Years
-14%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Research & Development
-$4.9B
CAGR 3-Years
-20%
CAGR 5-Years
-14%
CAGR 10-Years
-15%
No Stocks Found

Iovance Biotherapeutics Inc
Glance View

Market Cap
2.2B USD
Industry
Biotechnology

Iovance Biotherapeutics Inc. is navigating the intricate world of biotechnology with a bold mission: to develop innovative cancer immunotherapies that harness the power of the human immune system. Founded with the vision of transforming how cancer is treated, the company has journeyed through the challenging landscapes of medical research and regulatory scrutiny to bring forth groundbreaking treatments. At the heart of Iovance's strategy is its pioneering work in Tumor-Infiltrating Lymphocyte (TIL) therapy, a process that involves extracting, expanding, and then reinfusing a patient’s own immune cells to target and destroy cancerous tumors. This approach is not only novel but distinctly personal, as it effectively turns the patient's immune system into a bespoke tool against their cancer. The company's business model is centered around the successful clinical development and commercialization of these TIL therapies. As it advances its lead product candidates through critical phase trials, Iovance aims to secure FDA approval, which would transition these therapies from promising research to viable medical treatments. The financial backbone of Iovance comes from its ability to attract investors and establish partnerships, which fund the expensive and time-consuming research and development phase. Its revenue-generating potential will largely depend on the approval and subsequent adoption of its therapies, positioning it within the broader oncology treatment market, which is both highly competitive and highly lucrative. In this demanding arena, Iovance finds itself competing not just on the efficacy of treatments, but also on its capacity to scale production and navigate the complexities of healthcare pricing and reimbursement.

IOVA Intrinsic Value
6.73 USD
Overvaluation 9%
Intrinsic Value
Price

See Also

What is Iovance Biotherapeutics Inc's Research & Development?
Research & Development
-297.6m USD

Based on the financial report for Sep 30, 2024, Iovance Biotherapeutics Inc's Research & Development amounts to -297.6m USD.

What is Iovance Biotherapeutics Inc's Research & Development growth rate?
Research & Development CAGR 10Y
-69%

Over the last year, the Research & Development growth was 12%. The average annual Research & Development growth rates for Iovance Biotherapeutics Inc have been -8% over the past three years , -16% over the past five years , and -69% over the past ten years .

Back to Top